S. Korea Panel Recommends Restricting Painkillers To 15 And Older
This article was originally published in PharmAsia News
South Korea's drug regulator is expected to accept a recommendation that certain painkillers be restricted to persons 15 years of age and older. Among the drugs on a list drafted by the Central Pharmaceutical Affairs Council were popular medicines such as Bayer Korea's Saridon-A and Samjin Pharm's Geworin because their active pharmaceutical ingredient is isopropylantipyrine. The council said in its recommendation to the South Korea FDA the drug can cause heart disorders and loss of consciousness and should not be available to people under the age of 15. (Click here for more
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.
Alvogen believes it is the first company to file for a generic pazopanib rival to Novartis’ Votrient oncology brand in Europe.